Previous studies targeting mTOR signaling in cancer have focused on allosteric inhibition of mTORC1, but not mTORC2; therefore, the anticancer activity may be attributed to incomplete inhibition of the mTOR pathway [9,18]. Here, MTOR is linked to cancer.